About 20 years ago, Claudia Bagni and her team made a curious discovery: FMR1, the gene underlying most cases of fragile X syndrome, was strongly expressed in human cancer tissues.
At first, Bagni brushed it off as a fluke. FMR1 had no known roles in processes related to cancer, such as cell proliferation. But over time, she started to see evidence for a connection build. According to her own findings and those of other scientists, as well as a handful of small epidemiological studies and case reports, it seemed that people with fragile X, the most common form of inherited intellectual disability, might be protected from cancer.
Those initial clinical reports marked for our group the beginning of a new, completely unexplored [research] area connecting neuroscience and cancer biology, says Bagni, now director of fundamental neurosciences at the University of Lausanne in Switzerland.
In the past decade, Bagni and others have shown that several different types of cancer including colon cancer, liver cancer, pancreatic cancer and melanoma involve increased levels of FMRP, the protein encoded by FMR1. In a mouse model of breast cancer, having high levels of FMRP in tumors is linked to the spread of the cancer to other areas of the body, including the lungs, according to a 2013 report. And the list keeps growing.
Bagnis latest study, published last month in Cell Death & Disease, identified high levels of FMRP in tumors from people with glioblastoma, an aggressive cancer of the brain or spinal cord. The patients FMRP levels tracked not only with tumor growth but with their overall survival. Whats more, overexpressing FMRP in glioblastoma stem-like cells, which are thought to be involved in tumor initiation, also boosted cell proliferation in a lab dish.
The new results reinforce FMRPs link to cancer and the idea that people with fragile X syndrome may have an unusually low risk for it, says Randi Hagerman, medical director of the MIND Institute at the University of California, Davis, who was not involved in the work. People with fragile X, who often have autism as well, have mutations that silence FMR1 and prevent cells throughout the body from producing FMRP.
[The new work] also suggests a new treatment for glioblastoma, which is a terrible kind of cancer, Hagerman says.
But research on exactly how FMRP levels might influence a persons cancer risk is still in its infancy and how to investigate the connection to fragile X isnt straightforward, says Nien-Pei Tsai, associate professor of molecular and cellular biology at the University of Illinois Urbana-Champaign.
It needs much more work to say that people with fragile X syndrome have a lower risk of developing cancer, Tsai says, noting that FMRP is lost during development, and its long-term absence could lead to compensatory effects later on.
When compensatory effects are in place, the correlation between the levels of FMRP and cancer progression may not be the same anymore, he adds. There is no easy way to test how [fragile X syndrome] may reduce risk for cancer.
Epidemiology studies might seem like the most direct way to establish the cancer-fragile X connection. National registries, such as those in Sweden, Denmark and Finland, track the condition as well as newly diagnosed malignancies, says Sven Sandin, a biostatistician at the Karolinska Institutet in Stockholm, Sweden. With that information, he says, its not that tricky to do a straight-on analysis.
But, he notes, potential confounds abound: If we have an increase in fragile X diagnoses because of increasing awareness and testing, and if at the same time we diagnose more children with cancer, that by itself would create a spurious association, he says.
Its also difficult to definitively connect the dots through FMR1. The FMRP protein binds to hundreds of RNA molecules in the brain and other tissues, affecting numerous signaling pathways some of which help regulate brain development and are also implicated in cancer development.
The cancer connection is not unique to FMR1. More than 40 genes associated with autism, including PTEN, TSC1 and TSC2, have links to cancer. Studies suggest that some autistic people have decreased odds of developing cancer, although those with co-occurring intellectual disability or birth defects are at a higher risk of cancer early in life than are non-autistic people, according to an April report.
If cancer genes were not involved in autism, it would be a miracle: They are all over the place theyre involved in virtually every aspect of signal transduction that occurs in the organism, says Michael Wigler, professor of cancer research at Cold Spring Harbor Laboratory in New York. Theres no simple story here.
If cancer genes were not involved in autism, it would be a miracle: They are all over the place. Michael Wigler
Yet the link to fragile X seems particularly robust, based on reports collected over the past 20 years. Among 223 Danish people with fragile X syndrome, only three had cancer, according to a 2001 study. This proportion is about 70 percent lower than whats expected in the general population. Another study, conducted in Finland, found that 11 out of 302 people with fragile X had cancer about 20 percent lower than whats expected in the general population.
A third report described the case of a boy with fragile X who developed an inoperable form of glioblastoma, but who survived for at least eightyears after the cancer diagnosis, with the tumor growing at a lower-than-expected rate. Children with glioblastoma typically survive one to six years after diagnosis, and less than 20 percent survive five years after diagnosis.
A range of mechanisms could be at play: Two genes overexpressed in people with fragile X are related to tumor suppressors, a 2010 study found. And among the genes whose levels were decreased in more than half of people with the syndrome in that study, one encodes a component of the Wnt/beta-catenin pathway. This pathway regulates cell growth and has been implicated in both cancer and neurodevelopmental conditions such as autism. Bagnis latest work on glioblastoma also hints at Wnt involvement: Reductions in FMRP levels, she and her colleagues found, dampen Wnt signaling.
If youre trying to identify converging pathways, Wnt signaling could be one of them, says Peng Jin, professor of human genetics at Emory University in Atlanta, Georgia.
But FMRP also targets vimentin, a protein that is associated with increased metastatic potential, Hagerman says. Vimentin allows the cancer to invade tissues, and if FMRP is high, it suggests there might be metastases too.
And another FMRP target is MDM2, a protein that hinders the maturation of neurons and is expressed at increased levels in people with fragile X syndrome. A compound being tested in cancer clinical trials, nutlin-3, inhibits MDM2 and boosts the number of mature neurons in a fragile X mouse model. It can also reverse cognitive and behavioral difficulties in the model, according to a study published in May.
We were looking for molecular pathways that could be modulated to correct what is dysregulated in the mice, says lead investigator Xinyu Zhao, professor of neuroscience at the University of Wisconsin-Madison. It turns out that some of them are indeed cancer drug targets.
Singling out any of these potential contributors could prove difficult. FMRP appears to have certain functions in some types of cells and not in others, says Ethan Greenblatt, assistant professor of biochemistry and molecular biology at the University of British Columbia in Canada. It may also have cell type-specific functions in cancer, affecting only some cancers.
And whether children with certain neurodevelopmental conditions are at higher or lower risk for malignancies may depend on the nature of the molecules involved, Jin says.
FMRP acts as a brake to suppress protein translation, whereas other molecules could be involved in gene activation, he says. Different molecules can play distinct roles in regulating neuronal function as well as cell proliferation.
Ultimately, Wigler says, a link may exist between FMRP and only some malignancies, with no direct tie between cancer and fragile X syndrome or other neurodevelopmental conditions.
Regardless, looking at that tie could lead to fresh therapeutic targets for several conditions. Something that downregulates FMRP could help with glioblastoma and downregulation of FMRP may be really helpful for many other cancers, Hagerman says. And, Bagni adds, identifying molecular pathways downstream of FMRP that are dysregulated in cancer cells could also lead to more targeted treatments for fragile X.
Cite this article: https://doi.org/10.53053/XLXD4405
See the original post here:
The cloudy connection between fragile X and cancer - Spectrum
- CIRI calls for safety advice revamp after health concerns raised by 3D printing emission research - 3D Printing Industry - October 13th, 2022
- Global Adult Stem Cells Market | Expected to Reach USD 9.45 Billion and Compound Annual Growth Rate (CAGR) is - openPR - October 4th, 2022
- CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumors - The Fresh Toast - June 22nd, 2022
- How Protein Nanoparticle Vaccines Have The Potential To Be Developed Into 'Safer' Covid-19 Vaccines: Study - ABP Live - June 4th, 2022
- SpaceX capsule returns to Earth with first all-private space station crew Spaceflight Now - Spaceflight Now - May 2nd, 2022
- Identifying Missing Links - and Why Certain Drugs Don't Work - in Alzhiemer's - BioSpace - April 6th, 2022
- Axion BioSystems Acquires Live-Cell Imaging Innovator CytoSMART Technologies - Business Wire - March 25th, 2022
- Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company - GlobeNewswire - December 24th, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) That Could Enhance HSC Gene Therapy and... - November 8th, 2021
- BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting &... - November 8th, 2021
- Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and... - November 8th, 2021
- MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual... - November 8th, 2021
- Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and... - November 8th, 2021
- Role of Stem Cells in Treatment of Neurological Disorder - October 16th, 2021
- A plant that 'cannot die' reveals its genetic secrets - The Independent - August 5th, 2021
- Exploring science with a new generation of girls - US Embassy in Georgia - February 11th, 2021
- Stemcell Renewal Elixir GEORGIA LOUISE - September 25th, 2020
- COVID is shifting the conversation about the medical application of CBD - Open Access Government - September 22nd, 2020
- Robert E. Windsor, MD, is being recognized by Continental Who's Who - PRNewswire - September 22nd, 2020
- Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer - Yahoo... - June 6th, 2020
- Athens hospital using biologic treatment on COVID-19 patients - Online Athens - June 2nd, 2020
- Study reveals birth defects caused by flame retardant - University of Georgia - June 2nd, 2020
- Novant Health Initiates Phase 2b/3 Trial with CytoDyns Leronlimab for Severely and Critically Ill COVID-19 Patients - Yahoo Finance - May 11th, 2020
- CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries -... - May 5th, 2020
- Covid-19 has shuttered labs. It could put a generation of researchers at risk - STAT - May 5th, 2020
- CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable... - May 5th, 2020
- Stem Cell Therapy in Atlanta, GA - sipapain.com - February 3rd, 2020
- Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2025 - News Distribute - December 27th, 2019
- Transition to exhaustion: clues for cancer immunotherapy - 7thSpace Interactive - December 5th, 2019
- Autologous Stem Cell And Non Stem Cell Based Therapies Market Opportunity Analysis and Industry Forecast up to 2026 - Guru Online News - November 20th, 2019
- Georgia solar factory scores on tariffs; others in industry take a hit - Atlanta Journal Constitution - September 23rd, 2019
- Georgia Stem Cells | Stem Cell TV - September 7th, 2019
- Current Strategies and Challenges for Purification of ... - March 6th, 2019
- Stem Cell Savannah Georgia 31401 - January 20th, 2019
- Atlanta, Georgia Stem Cell Transplant, Marietta, Berkeley ... - September 7th, 2018
- Placenta | Amniotic tissue is not stem cell therapy - Dr ... - July 17th, 2018
- Turning Skin Cells Into Brain Cells - 06/28/2012 - October 1st, 2017
- This Wasp's Larvae Sometimes Grow Hundreds of Soldier ClonesBut Why? - Entomology Today - August 21st, 2017
- Atlanta Stem Cell Therapy | Georgia Stem Cell Treatments ... - October 7th, 2016
- Storing Stem Cells In Teeth For Your Familys Future Health - October 31st, 2015
- Scientists Turn Back the Clock on Adult Stem Cells Aging ... - October 16th, 2015
- Lymphoid Cells, Lymphoid Stem Cells - AllCells.com - October 11th, 2015
- Using Stem Cells in Teeth for Future Use in Developing ... - September 30th, 2015
- Human Mesenchymal Stem Cells & Media - September 25th, 2015
- Asymmetrex Plans to Report Results From Adult Stem Cell ... - August 2nd, 2015
- Stem Cells - Lonza - July 10th, 2015
- Global Stem Cells Group Announces First Stem Cell Training ... - June 3rd, 2015
- Effective Hematopoietic Mesenchymal Stem Cell Therapies - April 25th, 2015
- Stem Cells Hashimoto's Thyroiditis - April 22nd, 2015
- Welcome to Atlanta Stem Cell Treatment - April 9th, 2015
- Stem Cells Thailand - Stem Cell Therapy Thailand - March 27th, 2015
- Stem Cell Institute Los Angeles Chronic Pain Treatments - March 27th, 2015
- Graphene Shows Promise In Eradication Of Stem Cancer Cells - March 10th, 2015
- Stem Cell Treatment India,Stem Cell Treatment India,Cost ... - March 8th, 2015
- Bone Marrow & Stem Cell Transplant Center | Atlanta, GA ... - November 16th, 2014
- Biological fat with a sugar attached essential to maintaining the brain's supply of stem cells - November 3rd, 2014
- How stress ups depression risk - October 21st, 2014
- Protein appears to protect against bone loss in arthritis - September 13th, 2014
- Boron Facilitates Stem Cell Growth and Development in Corn - August 29th, 2014
- Georgia (Stem Cell) - what-when-how - August 26th, 2014
- Stem Cells in GA - Georgia Bio - August 25th, 2014
- Stem Cells COPD | Stem Cell Treatments - August 23rd, 2014
- Stem Cells Atlanta GA, Stem Cell Therapy, Dental Stem Cells - August 22nd, 2014
- Stem cells reveal how illness-linked genetic variation affects neurons - August 22nd, 2014